Related Experiment Video

Updated: Oct 5, 2025

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.3K

Protein Tyrosine Phosphatase 1B (PTP1B): Insights into its New Implications in Tumorigenesis

Pei-Jie Chen1, Yun-Tian Zhang2,3

  • 1The Fourth Affiliated Hospital, Anhui Medical University, Hefei 230012, China.

Current Cancer Drug Targets
|January 28, 2022
PubMed

Insights

Protein tyrosine phosphatase 1B (PTP1B) is crucial in cancer development. This review explores PTP1B

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Tyrosine phosphorylation is a key regulatory process in cells, tightly controlled by kinases and phosphatases.
  • Dysregulation of tyrosine phosphorylation is implicated in various human diseases, notably cancers.
  • Protein tyrosine phosphatase 1B (PTP1B) is a non-transmembrane phosphatase historically linked to metabolic disorders but increasingly recognized for its role in cancer.

Purpose of the Study:

  • To review the multifaceted roles of PTP1B in the initiation and progression of diverse cancer types.
  • To elucidate the molecular mechanisms by which PTP1B influences cancer development.
  • To discuss the therapeutic potential of PTP1B inhibitors as anti-cancer agents.

Main Methods:

  • Literature review of recent studies on PTP1B function in cancer.
  • Analysis of molecular pathways regulated by PTP1B in oncogenesis.
  • Evaluation of preclinical and clinical data on PTP1B inhibitors for cancer therapy.

Main Results:

  • PTP1B actively participates in the regulation of key signaling pathways driving cancer cell proliferation, survival, and metastasis.
  • Specific mechanisms involve PTP1B's interaction with receptor tyrosine kinases and other oncogenic proteins.
  • Emerging evidence highlights PTP1B as a promising therapeutic target for various malignancies.

Conclusions:

  • PTP1B is a significant contributor to cancer pathogenesis across multiple tumor types.
  • Targeting PTP1B offers a potential strategy for novel cancer therapies.
  • Further research into PTP1B inhibitors is warranted for clinical application in oncology.
Keywords:
Protein Tyrosine Phosphatase (PTP)Protein Tyrosine Phosphatase 1B (PTP1B)cancertumor promotertumor suppressortyrosine phosphorylation

More Related Videos

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases06:56

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases

Published on: September 6, 2024

488
A Mass Spectrometry-Based Approach to Identify Phosphoprotein Phosphatases and their Interactors10:17

A Mass Spectrometry-Based Approach to Identify Phosphoprotein Phosphatases and their Interactors

Published on: April 29, 2022

2.5K

Related Concept Videos

Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
13.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.1K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
14.8K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K